Integrating AI in gastrointestinal endoscopy enhances image analysis, reduces diagnostic variability, and improves patient ...

5. The guidance recommends advanced or immunomodulatory therapy after failure of 5-aminosalicylates instead of a "step-up" approach. The recommendations also define moderate to severe disease using a ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...

[31] Our definition of ulcerative colitis therefore remains based on clinical, endoscopic and histologic criteria that were established over several decades -- a diffuse, continuous and ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

The studies also demonstrated endoscopic improvement with the drug ... to include moderately to severely active ulcerative colitis based on findings from QUASAR, an ongoing phase IIb/III induction ...

LEADING Austrian health experts gathered at UEG Week 2024 to push forward the implementation of a nationwide, quality-assured ...

Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as ... symptomatic, endoscopic and histologic endpoints ...

The topline results indicate that ABX464 was safe, well-tolerated, and demonstrated statistically significant efficacy based on both clinical and endoscopic ... need in ulcerative colitis, as ...